SRT 3025

Drug Profile

SRT 3025

Alternative Names: SRT-3025

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sirtris
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in United Kingdom (PO, Capsule)
  • 23 Nov 2011 Sirtris completes enrolment in its phase I trial for Type 2 diabetes mellitus in USA (NCT01340911)
  • 26 Jul 2011 Phase-I clinical trials in Type-2 diabetes mellitus in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top